Welcome to our dedicated page for Renovacor news (Ticker: RCOR), a resource for investors and traders seeking the latest updates and insights on Renovacor stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Renovacor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Renovacor's position in the market.
Renovacor (NYSE: RCOR) has successfully completed its business combination with Chardan Healthcare Acquisition 2 Corp, raising $95.1 million in gross proceeds. The company reports positive preclinical results for REN-001, showing effective cardiac transduction in a pilot pig study. Key appointments to the leadership team include Marc Semigran, M.D. as CMO. Full-year 2021 net loss was $14.1 million, with R&D expenses at $11.8 million. Renovacor expects to submit an IND for REN-001 in H2 2022 and initiate a Phase I/II trial for BAG3-DCM thereafter.
Renovacor, a biotechnology company focused on precision therapies for genetically-driven cardiovascular diseases, announced a corporate overview presentation by CEO Magdalene Cook at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 9:10 a.m. ET. This event will showcase Renovacor's lead program targeting BAG3-associated dilated cardiomyopathy, a severe heart failure condition. A webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-conference.
Renovacor, Inc. (AMEX: RCOR) announced partnerships with the Dilated Cardiomyopathy Foundation, Heart Failure Society of America, and American Association of Heart Failure Nurses. The collaborations aim to raise awareness about genetically-driven cardiovascular diseases and the importance of genetic testing for patients with dilated cardiomyopathy (DCM). Renovacor focuses on innovative therapies, particularly for monogenic causes like BAG3-associated DCM. The company promotes initiatives aligned with Rare Disease Day, highlighting genetic contributions to cardiovascular health.
Renovacor, a biotechnology company listed on AMEX under the symbol RCOR, will have its CEO, Dr. Magdalene Cook, participate in the 11th Annual LifeSci Partners Corporate Access Event on January 6, 2022. The panel presentation titled Gene Therapy: Reaching its Full Potential is scheduled for 11:00 a.m. ET. Investors can view the presentation via a webcast link provided in the announcement. Renovacor focuses on innovative therapies for genetically-driven cardiovascular diseases, particularly through its lead program targeting BAG3-associated dilated cardiomyopathy.
Renovacor, Inc. (NYSE: RCOR) debuted as a public company with $95.1 million in gross proceeds from its merger with Chardan Healthcare Acquisition 2 Corp. and concurrent PIPE financing. The company announced positive preclinical data for REN-001, demonstrating effective delivery via retrograde coronary sinus infusion. Recent leadership enhancements include the appointment of Dr. Matthew Killeen as CSO and Dr. Elizabeth White as CBO. Financial results for Q3 2021 showed a net loss of $8.2 million, with a cash position of $85.3 million, projected to sustain operations into 2023.
Renovacor, Inc. (NYSE: RCOR) has appointed Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations, enhancing its leadership team in the development of AAV-based gene therapies. Dr. Dhanasekharan brings over a decade of experience in technical operations, previously working with SwanBio Therapeutics and Amicus Therapeutics. This strategic move aims to support the anticipated IND filing for Renovacor’s lead product, REN-001, targeting BAG3 gene mutation-related diseases, particularly in heart failure models. The company focuses on addressing high unmet medical needs in cardiovascular health.
Renovacor, Inc. (NYSE: RCOR) announced that CEO Magdalene Cook will participate in a fireside chat at the Chardan Virtual 5th Annual Genetics Medicines Conference on October 5, 2021, at 11:30 a.m. EDT. This event will focus on Renovacor's gene therapies for cardiovascular and central nervous system diseases caused by BAG3 gene variants. A webcast will be available on Renovacor's website, with a replay accessible for 30 days post-event. Renovacor develops innovative AAV-based therapies, primarily targeting BAG3 mutation-associated dilated cardiomyopathy.
Renovacor, Inc. (NYSE: RCOR) announced the appointment of Dr. Jordan Shin as Senior Vice President of Clinical Development and Translational Science. With nearly two decades of experience, Dr. Shin is expected to significantly contribute to advancing Renovacor's lead program, REN-001, aimed at treating BAG3 gene variant-associated cardiovascular diseases. The company anticipates filing for an Investigational New Drug (IND) application for REN-001 in mid-2022, following its recent public market entry after a merger and financing. This strategy targets a high unmet medical need in genetics-driven cardiomyopathy.
Renovacor, Inc. (NYSE: RCOR) announced that its CEO, Magdalene Cook, will participate in a fireside chat at the 2021 Wells Fargo Healthcare Conference on September 9, 2021, at 10 a.m. EDT. This event will focus on the company's development of AAV-based gene therapies targeting BAG3 gene variants associated with cardiovascular and CNS diseases. Interested parties can access the webcast on Renovacor's website, with a replay available for 30 days post-event.
FAQ
What is the market cap of Renovacor (RCOR)?
